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Abstract
Complex and intricate circuitries regulate cellular proliferation, survival, and growth, and 
alterations of this network through genetic and epigenetic events result in aberrant cellular 
behaviors, often leading to carcinogenesis. Although specific germline mutations have been 
recognized as cancer inducers, the vast majority of neoplastic changes in humans occur through 
environmental exposure, lifestyle, and diet. An emerging concept in cancer biology implicates the 
microbiota as a powerful environmental factor modulating the carcinogenic process. For example, 
the intestinal microbiota influences cancer development or therapeutic responses through specific 
activities (immune responses, metabolites, microbial structures, and toxins). The numerous effects 
of microbiota on carcinogenesis, ranging from promoting, preventing, or even influencing 
therapeutic outcomes, highlight the complex relationship between the biota and the host. In this 
review, we discuss the latest findings on this complex microbial interaction with the host and 
highlight potential mechanisms by which the microbiota mediates such a wide impact on 
carcinogenesis.
Introduction
Cancer is a multifactorial disease involving genetic and epigenetic alterations, environmental 
factors, and lifestyle components. Cancer genetic studies have offered a spectacular view of 
the complexity and intricacy of events at play during carcinogenic evolution.1-3 Similarly, 
significant progress has been made on the identification and functional effect of 
environmental elements and lifestyles on tumorigenesis.4 As a whole, these studies have 
contributed important knowledge regarding mechanisms implicated in cancer initiation, 
progression, metastasis, and therapeutic responses. Beside the previously mentioned factors, 
a relatively novel component named the microbiota has recently been recognized as a potent 
modulator of the carcinogenic process. The microbiota is a consortium of microorganisms 
composed of bacteria, viruses, fungi, and protozoa living in various body sites, including 
oral,5 urogenital,6 and gastrointestinal (GI) cavities,7 forming a community living in a 
eubiotic state. Noteworthy, genetic, environmental, and lifestyle components all influence 
microbial composition and one should not view these as independent factors but rather as 
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integrated components of carcinogenesis8 (Fig 1). The vast majority of microorganisms 
reside within the intestine, and influence not only the local gut function but also exert long-
distant effects on host homeostasis and disease states such as allergy, asthma,9 rheumatoid 
arthritis,10 cardiovascular diseases,11 metabolic syndrome,12 and obesity.12,13 This review 
will focus on recent advances about the local and wide range effects the intestinal microbiota 
exerts as it mediates numerous phases of cancer, particularly colorectal cancer (CRC), 
spanning initiation, progression, and treatment.
The mechanisms by which the microbial community exerts such a profound and wide 
impact on the host are still unclear but likely originate from microbial metabolism and 
microbial-derived structures interacting with the host cellular compartment through 
receptors or receptor-independent fashion. Moreover, the identities of specific 
microorganisms responsible for health maintenance or disease development are still unclear 
and probably result from an ensemble of organisms rather than any particular one. A general 
consensus in the field is that alterations in the microbiome, a phenomenon termed dysbiosis, 
are often linked to disease development, including CRC.14 In addition, preclinical models 
suggest that microbial dysbiosis has a causative impact on cancer development, at least for 
CRC. As such, some forms of cancer may be influenced by the action of a microbial 
community as opposed to a single organism paradigm as seen with Helicobacter pylori 
(gastric cancer), hepatitis B or C virus (liver cancer), or Epstein–Barr virus (lymphomas) 
infection.15
Microbial Dysbiosis and Tumorigenesis
Although numerous body sites have been shown to harbor a microbiota, the intestine has the 
most compelling evidence that microbial composition is linked to carcinogenesis. In this 
pathology, phylogenic differences were reported between bacteria present in the intestine of 
healthy subjects compared with CRC patients.16 Microbial dysbiosis is also observed 
between tumor and healthy adjacent tissue of the same patient,17 distal vs proximal 
tumors,18 and between tumor staging from adenoma to adenocarcinoma.19 A systematic 
review of reports documented microbial dysbiosis in CRC patients highlighting specific 
changes within the intestinal microbial community such as increased representation of 
fusobacteria, Alistipes, porphyromonadaceae, coriobacteridae, staphylococcaceae, 
Akkermansia, and methanobacteriales and decreased abundance of Bifidobacterium, 
Lactobacillus, Ruminococcus, Faecalibacterium, Roseburia, and Treponema.14 In line with 
microbial dysbiosis, novel prognostic approaches have made use of the unique microbial 
signature present in patients to predict the carcinogenic stage, a step toward the generation 
of noninvasive biomarkers to test stools.20-22 In addition, microbial dysbiosis has also been 
observed in other forms of cancers including breast, lung, urogenital, and liver, which was 
the subject of a recent review.23
Independent of dysbiosis, the intestinal microbiota may play an important role in the 
progression of extra-intestinal cancer. A study analyzing public data to assess bacterial DNA 
integration into the somatic genome identified leukemia as having the highest number of 
reads, with a high frequency of Acinetobacter gene transfer into leukemic cells.24 In 
addition, mice genetically predisposed for B-cell lymphoma, another form of blood cancer, 
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exhibit delayed disease and a distinct separation in bacterial diversity when exposed to 
stringent husbandry conditions or associated with a restricted microbiota in contrast to being 
housed or raised in specificpathogen-free (SPF) conditions.25 These data suggested a 
causative role for the microbiota in disease progression. For some time, studies have linked 
H. pylori to mucosa-associated lymphoid tissue lymphoma.26 Accordingly, treatment with 
antibiotics to deplete H. pylori resulted in regression of disease.27 Strikingly, low-grade 
mucosa-associated lymphoid tissue patients with undetectable levels of H. pylori that were 
subjected to the standard H. pylori eradication treatment, containing a mixture of antibiotics, 
showed complete remission of disease,28 suggesting an even broader mechanistic role for 
intestinal microbiota in lymphoma beyond H. pylori infection.
Studies in preclinical models support a causal role for dysbiosis in CRC. For example, the 2 
most commonly used models of colon tumorigenesis, the adenomatous polyposis coli 
(ApcMin/+) spontaneous model and the colitis-associated cancer (CAC) model involving the 
procarcinogenic compound azoxymethane (AOM) and the inflammatory agent dextran 
sodium sulfate (DSS), showed differences in the microbiota of mice with tumors vs 
controls.29,30 Son et al compared the gut microbial composition between ApcMin/+ and wild-
type (WT) mice at the age of 6 weeks, a stage preceding intestinal neoplasia, and showed the 
presence of dysbiosis.30 Germ-free (GF) studies have greatly expanded the depth of research 
in the microbiota field allowing the ability to study specific contributions of a single 
bacterial species or communities. These studies, along with many additional cancer models, 
including those of the gut, lung, breast, and immune system, underline a role for the 
microbiota in tumor development.31 It is important to note that the role of bacteria in CRC 
development may be model specific. For example, GF AOM/DSS mice develop more tumors 
compared with SPF mice, which was attributed to delayed inflammatory and proliferative 
responses.32 However, for most CRC murine models including AOM/IL10−/− and ApcMin/+ 
mice, GF mice typically develop fewer tumors.31 Altogether, these data highlight a direct 
link between dysbiosis and tumor development. It is important to note that the cross talk 
between microbiota and cancer can be bidirectional as cancer may provide an environment 
fostering changes in microbial composition, which could then further influence 
carcinogenesis.
In addition to microbiota composition, the organization and location of the microbiota in 
CRC patients also impact tumorigenesis. For example, bacterial bio-films were recently 
identified in 50% of tumor and paired adjacent normal tissue samples from human CRC 
patients using fluorescence in situ hybridization.33 In addition, stratifying CRC patients by 
tumor location revealed biofilms associated with 89% of right-sided (proximal) CRCs vs 
13% of left-sided (distal) CRCs.33 The presence of a biofilm on CRC patient normal tissue 
was associated with increased epithelial interleukin (IL)-6 expression, Stat3 
phosphorylation, and epithelial cell proliferation and decreased E-cad-herin expression, 
suggesting a possible mechanism by which biofilms drive tumorigenesis.33 On the microbial 
side, metabolites may partly explain how biofilms contribute to tumorigenesis.34 Indeed, 
higher levels of acetylated polyamines were detected in biofilm-positive cancer tissue 
compared with biofilm-negative cancer tissue.34 In addition, antibiotic treatment of CRC 
patients eliminated the presence of a biofilm and was associated with decreased acetylated 
polyamines in tumor and paired normal tissue substantiating the association between 
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bacterial biofilms and acetylated polyamines.34 Further studies are needed to address other 
mechanisms by which biofilms promote cancer as acetylated polyamines are significantly 
higher in CRC patient tumor tissue compared with normal tissue regardless of biofilm 
status.34
Diet, Microbiota, and Host Mechanisms
Components of the diet that cannot be digested in the GI tract are biotransformed by the 
microbiota to generate critical nutrients and metabolites for the host. The type of diet 
consumed by the host has a profound impact on the spectrum of bacterial-derived 
metabolites, a phenomenon that could have important repercussions for homeostasis. For 
example, the microbial-derived metabolomic signature of vegans is significantly different 
than omnivore subjects,35 although the functional impact of these metabolites on health 
status is unclear. Nevertheless, knowing the strong link between diet and cancer 
development, the biotransformation function of the microbiota has drawn intense attention. 
One of the earliest and most widely known associations between diet and cancer was that 
involving red meat. Consumption of red meat leads to the production of dietary heme, which 
has been shown to have host cytotoxic effects.36 The microbiota was recently identified as a 
mediator of heme-induced preneoplastic events, which include hyperplasia and hyper-
proliferation.37 Administration of heme-supplemented diet in mice was sufficient to 
augment bacterial load with a significant increase in Bacteroides abundance and host cellular 
proliferation. These data support a direct connection among diet, the microbiota 
composition, and the host function.
Of interest are recent studies identifying the micro-biota as a mediator of diet-induced 
modulation of host cellular processes, likely through the generation of selective metabolites. 
We direct readers to a series of comprehensive reviews highlighting the production and role 
of microbial metabolites including short-chain fatty acids (SCFAs) in cancer and immune 
homeostasis.38-40 One of the most recent human studies analyzing the tunable role of diet in 
cancer susceptibility was that of African Americans, influenced by a high-fat western diet 
that is strongly implicated in the etiology of many diseases including cancer, and the 
genetically similar rural African population having a more restricted diet that has a high 
fiber content. African Americans carry a greater risk for cancer development, specifically 
CRC, than White Americans.41 Moreover, cancer risk is more than 10-fold higher in African 
Americans than in rural Africans.42 The role of diet in this high-risk group was examined by 
studying fecal samples from African Americans and rural Africans.42,43 Rural Africans 
contained higher amounts of Prevotella, whereas African Americans were colonized more 
abundantly by Bacteroides.43 Further analysis of African American samples revealed 
enrichment of bile acids, known for their protumorigenic effects.44 Conversely, rural 
Africans were enriched for genes involved in the production of metabolites such as the 
SCFA butyrate, known for its protective, antitumorigenic effects in mice.45 The 
cytoprotective effects of butyrate have been shown to depend on the receptor Gpr109a, as 
genetic deletion results in a significant increase in colonic tumors.46 Interestingly, diet 
intervention was able to alter the production of these microbial metabolites. When African 
Americans were switched to a high-fiber, low-fat diet, an increase in butyrate-producing 
microbes was observed.42 In contrast, when rural Africans were switched to a high-fat, low-
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fiber diet, an increase in bacterial gene expression responsible for bile acid production was 
noted. The diet switch also reversed cellular proliferation and immune cell infiltration in 
colonic biopsies of the subjects, suggesting that dietary changes modulate microbiota 
activities, leading to functional consequences on the host.
As stated in the previous section, bacteria and their associated metabolites could impact 
carcinogenesis at extraintestinal locations. Many of these long-range effects are because of 
metabolite dissemination throughout the body, with or without further transformation by the 
liver.47,48 For example, high-fat diet can promote hepatocarcinogenesis through microbial 
metabolic activities. In a carcinogen-driven model of tumorigenesis using the chemical 
dimethylbenz(a) anthracene, administration of high-fat diet resulted in a significant increase 
in liver tumor burden. This was shown to be a result of diet-induced intestinal dysbiosis 
responsible for the increased production of the secondary bile acid, deoxycholic acid.49
Knowledge of the influence diet intervention plays in microbial output can also be used for 
the benefit of the host. Leukemia is commonly associated with cachexia, a frequent adverse 
effect to most cancers that is characterized by decreased muscle mass and energy loss. 
Exploitation of the microbiome's metabolic function using nondigestible carbohydrates has 
been shown to reverse these effects.50,51 Nondigestible carbohydrates serve as precursors for 
microbial production of SCFAs and their effect resulted in increased muscle mass and 
reduced inflammation.51 In addition, when combined with the bacterial administration of 
Lactobacillus reuteri, known as synbiotic approach, intestinal homeosta-sis was restored and 
cytokine production and immune cell recruitment that was observed during carcinogen-esis 
were reversed in mice.50
Altogether, these studies highlight the pronounced effect of diet on the microbiota and its 
functional consequences on the host.
Interplay Among Host Immunity, Microbiota, and Crc
As mentioned in the previous section, the microbiota has been implicated in multiple types 
of cancer, but the mechanisms by which bacteria influence carcinogenesis are still unclear. It 
is clear that numerous processes are at play during bacteria-induced carcinogenesis, one of 
which is the ability of microorganisms to induce inflammation on recognition by the host 
innate immune system.52 There is considerably more information on the immune 
mechanisms involved in CRC driven by the microbiota, and this section will highlight the 
recent developments in this field. Pattern recognition receptors (PRRs) are part of the host 
innate immune response and include C-type lectin receptors, helicase receptors, toll-like 
receptors (TLRs), and the NOD-like receptor (NLR) family.53 PRRs sense microbes 
(microbe-associated molecular patterns) and tissue damage (damage-associated molecular 
patterns) and play crucial roles in maintaining host and microbiota homeostasis (eubiosis).53 
Dysregulation of PRRs has been linked to multiple inflammatory disorders including obesity 
and inflammatory bowel disease (IBD), both of which are risk factors of CRC.54-56 IBD 
patients have an estimated 2%–40% risk of developing CAC depending on IBD severity, 
duration, and location.57
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Single-nucleotide polymorphisms in NOD2, an NLR member, have previously been 
implicated in IBD, and meta-analysis of 30 human cancer studies shows an association 
between several polymorphisms in the leucine-rich region of NOD2 and cancer risk, 
particularly for GI cancer.58 Furthermore, review of 10 CRC microarray expression data sets 
found reduced NLRC3 expression and increased NOD1 and NOD2 correlated with CRC.59 
Interestingly, Nod2-derived intestinal stem cell signaling promotes cellular proliferation 
after an injury,60 suggesting that bacteria could feed prolifer-ative signaling to stem cells.61 
In contrast, genetic deletion of Nod1 or Nod2 exacerbates CAC development, suggesting 
that these sensors exert protective functions against carcinogenesis.62,63 Overall, the data on 
NOD2 appear contradictory with NOD2 polymorphisms and increased NOD2 expression 
associated with human CRC, whereas in contrast CAC is worse in Nod2−/− mice.
Nod2 deficiency in mice resulted in microbiota dysbiosis that promoted inflammation and 
tumorigenesis in AOM/DSS-induced CAC through an IL-6–dependent mechanism.63 
Another study found that Nod2 control of microbiota composition is cell compartment 
specific as Nod2 deficiency in nonhematopoietic cells resulted in an altered microbiota, 
associated with altered mucin and antimicrobial peptide expression in the ileum and colon.64 
However, Nod2-mediated dysbiosis is controversial because a study using littermate controls 
(co-housed WT and Nod2−/− mice) failed to observe intestinal dysbiosis.65 It is unknown 
whether the NOD2 polymorphisms or increased NOD1/2 expression in human CRC patients 
are associated with an altered microbiota composition. Clearly, more studies are needed to 
address how NOD1/2 signaling modulates carcinogenesis and which bacteria contribute.
Another critical innate immune response implicated in gut homeostasis is inflammasome 
activation.53 This response is triggered by the sensing of various microbe-associated 
molecular patterns or damage-associated molecular patterns by specific sensors, leading to 
caspase-1 activation, which then cleaves pro–IL-1β and IL-18 proteins to generate functional 
cytokines.66 Gene expression patterns of inflammasome components in CRC microarray 
data sets revealed reduced NLRP1, NLRP3, NLRC4, and AIM2 in CRC patients compared 
with healthy controls.59 In the context of a CAC mouse model, Nlrp6 and the adaptor 
protein apoptosis-associated speck-like protein containing CARD (Asc) knockout mice are 
more susceptible to AOM/DSS-induced tumorigenesis than WT mice.67 Cohousing and 
antibiotic experiments revealed the involvement of the microbiota in tumorigenesis via 
induction of the inflammatory cytokines IL-18 and che-mokine (C-C motif) ligand 5, which 
promoted epithelial cell proliferation through IL-6.67 A metabolomic screen performed on 
cecal contents from WT and Asc−/− mice suggests that microbial metabolites modulate 
inflammasome signaling and consequently host response.68 For example, taurine, a bile acid 
component, was found to activate the Nlrp6-mediated inflam-masome, inducing 
antimicrobial angiogenin 4, promoting the epithelial barrier function, and restoring 
homeostasis.68 In contrast, histamine and the polyamine spermine were identified as 
microbial metabolites that inhibit Nlrp6 inflammasome activation and promote dysbiosis.68 
Although these studies suggest that micro-bial metabolites are able to modulate 
inflammasome signaling, the functional impact of these metabolites in human 
inflammasome activation remains to be defined. The Nlrp1, Nlrp3, and Nlrc4 
inflammasomes have also been implicated in regulating susceptibility to AOM/DSS-induced 
CAC, but the contribution of microbiota in these findings was not examined.69-71
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Migration of cancer cells from the organ of origin to other body sites, a process called 
metastasis, is a hallmark of late-stage cancer and poor prognosis.72 A model of CRC 
metastasis where mouse CRC cell lines are intrasplenically injected into mice showed that 
Nlrp3 suppresses metastatic growth to the liver.73 Nlrp3-mediated suppression of metastatic 
growth appeared to be microbially independent because antibiotic treatment did not alter 
liver metastasis.73 However, residual bacteria, bacterial products, or microbial-derived 
metabolites may still be present in antibiotic-treated mice. Stringent experiments involving 
GF mice are needed to define the relationship among NLRP3, bacteria, and metastasis.
Although, the cytosolic double-stranded DNA sensor, AIM2, was previously implicated in 
host defense against infection via inflammasome activation,74,75 2 groups have demonstrated 
a protective role for AIM2 in CAC and CRC mouse models that operates through an 
inflammasome-independent mechanism.76,77 In one study, Aim2 deficiency led to increased 
AOM/DSS-induced tumorigenesis by promoting stem cell proliferation.76 Microbiota 
dysbiosis accompanied tumorigenesis in Aim2−/− mice with an increased abundance of 
Akkermansia muciniphila and decreased Anaerostipes, Bifidobacterium, Flexispira, and 
Prevotella.76 Cohousing experiments reduced tumors in Aim2−/− mice and increased tumors 
in WT mice, suggesting Aim2 protection against CAC is dependent on microbiota.76 In the 
other study, Aim2 deficiency increased tumorigenesis in ApcMin/+ and AOM/DSS mice.77 
Additional experiments revealed that Aim2 associates with the PI3K-related family member, 
DNA-dependent protein kinase (DNA-PK) to limit Akt activation, controlling epithelial cell 
proliferation and apoptosis, although the role of the microbiota was not addressed in this 
study.77
Multiple proinflammatory cytokines are implicated in CRC pathogenesis, many of which are 
directly or indirectly affected by the microbiota.78 Increased IL-23 and IL-17A expressions 
are found in tumors from human CRC patients and in a spontaneous mouse model of CRC 
(CPC-APC mice) compared with normal tissue.79 Additional experiments with antibiotics or 
Myd88−/− and Tlr2,4,9−/− mice suggest the microbiota promotes IL-23 and IL-17A 
expressions. Decreased barrier protein expression and function in mouse and human CRC 
tissues suggests that infiltration of bacteria and microbial components (together or 
individually) promote tumor inflammation.79 Another IL-17 family cytokine, IL-17C, is also 
upregulated in tumors from human CRC patients and mouse CRC models (ApcMin/+, AOM/
DSS) in a TLR-MyD88–dependent signaling manner.80 IL-17C induces the prosurvival 
genes, Bcl-Xl and Bcl-2, in intestinal epithelial cells to promote tumor formation.80 The 
microbiota is implicated in IL-17C production because antibiotic-treated mice and GF mice 
exhibit reduced IL-17C messenger RNA expression.80 Importantly, Enterobacteriaceae 
abundance, in particular, was shown to be increased during DSS treatment and Escherichia 
coli monocolonized GF mice–induced IL-17C expression after DSS treatment.80 However, it 
is unknown whether increased Enterobacteriaceae in human CRC stool or tumor tissue 
samples is associated with increased IL-17C expression.
Mucosa-associated invariant T (MAIT) cells are innate-like T cells that can produce both 
interferon gamma (IFN-γ) and IL-17, which have been shown to promote either antitumor 
immunity or tumorigenesis, respectively.81 MAIT cells are activated by riboflavin (vitamin 
B2) metabolites, which are produced by bacteria and yeast, suggesting interaction with the 
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microbiota.82 To examine the role of MAIT cells in CRC, Sundström et al81 compared 
MAIT cell numbers and functional activities in colon tumor and unaffected tissue (>10 cm 
from tumor) from CRC patient resections. A higher accumulation of MAIT cells in tumor 
tissues was observed compared with unaffected tissues.81 Functionally, there was a lower 
frequency of IFN-γ producing MAIT cells in tumor tissue, which was attributed to factors 
present in the tumor microenvironment, as tumor tissue–conditioned medium decreased 
IFN-γ production in vitro. A similarly high number of MAIT cells in CRC tumors were 
observed in a separate study.83 However, these studies have not addressed the relationship 
between the microbiota and MAIT cell frequency and function in CRC, and further studies 
will be needed to define this possible interplay.
Autophagy can affect multiple aspects of the immune system: PRR signaling, 
proinflammatory signaling, adaptive immunity, and secretion of immune mediators.84 
Assessment of LC3 vesicular staining in human CRC samples and an Apc mouse model 
revealed autophagy genes are active during CRC.85 Conditional inactivation of the 
autophagy gene Atg7 in intestinal epithelial cells inhibits tumorigenesis in tamoxifen-treated 
VilCreERT2Apcflox/+ mice (Apc+/−Atg7−/−) by suppressing proliferation and enhancing 
antitumor CD8+ T cells.85 This phenotype is dependent on micro-biota because antibiotic-
treated Apc1/2Atg7−/− mice have a diminished antitumor response.85 In addition, 
Apc+/−Atg7−/− mice have disrupted gut mucosal integrity resulting in altered microbiota 
localization and composition with a higher abundance of firmicutes and a lower abundance 
of proteobacteria compared with Apc+/− mice.85 Thus, the microbiota influences a range of 
host immune responses including PRRs, inflammasomes, cytokines, MAIT cells, and 
immune responses affected by autophagy, all of which contribute to cancer susceptibility 
(Fig 2).
Immune Mechanisms Involved in Specific Bacteria-Driven CRC
Although the nature of microbial interactions with the host is polymicrobial, it is important 
to dissect the individual contributions of these microorganisms to carcinogenesis. Specific 
bacterial candidates implicated in human CRC include enterotoxigenic Bacteroides fragilis 
(ETBF), E. coli, and Fusobacterium nucleatum and have been shown to influence the 
carcinogenic process through various strategies including production of toxins, genotoxins, 
and specific microbial genes.31,86
Interestingly, some microbial activities impact host immune responses or are modulated by 
host-derived inflammation. Mucosal T regulatory lymphocytes (Tregs) have been shown to 
promote cancer initiation via the enhancement of IL-17A production in ETBF-colonized 
ApcΔ716 mice.87 Genetic depletion of Tregs for the first 2 weeks after ETBF colonization 
reduced microadenoma numbers but not inflammation (increased IFN-γ, decreased IL-17A) 
in Apc Δ716 mice, unexpectedly suggesting that Tregs enhance cancer initiation by 
promoting T helper 17 (Th17) differentiation through an IL-2–dependent mechanism.87 The 
cellular source of IL-17A in ETBF-colonized Apc Δ716 mice was examined by ablating 
IL-17 production via Stat3 inactivation in CD4+T cells (CD4Stat3−/−).88 Tumorigenesis was 
delayed in CD4Stat3−/− mice and their tumors still had increased IL-17A expression, 
suggesting the involvement of additional IL-17A–producing cells.88 γδT cells were 
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identified as the other IL-17A producers by flow cytometry of CD4Stat3−/− tumor tissue, 
which was then confirmed with bone marrow chimera experiments.88 In addition, the 
presence of both Th17 and γδT17 cells in human CRC tumor tissues suggests that both cell 
types contribute to IL-17A production in CRC, although the role of ETBF in this 
observation was not examined.88 Strikingly, ETBF seems important for both tumor initiation 
and progression in ApcΔ716 mice, as ETBF clearance with the antibiotic cefoxitin 5 or 14 
days after colonization differentially impacts IL-17A cytokine expression and adenoma 
numbers, with both time points reducing microadenoma formation.89
Colibactin is a microbial-derived genotoxin encoded on the pathogenicity island pks found 
predominantly in phylogroup B2 E. coli.90,91 This genotoxin induces double-strand DNA 
breaks and is essential for E. coli–induced CRC.91,92 Interestingly, microbial RNA-
sequencing suggests that host inflammation altered 3% of cancer-promoting genes in pks+ 
E. coli, including 5 pks island genes that were increased in E. coli monoassociated AOM/
IL10−/− compared with AOM IL10−/−; Rag2−/− mice.93 Among these pks genes was clbM, 
which was recently identified as a multi-antimicrobial extrusion protein transporter of 
precolibactin.94 High abundance of Enterobacteriaceae is observed in CRC patients and in 
mouse models of CRC,95 but the fact that pks+ E. coli failed to promote CRC in AOM/
IL10−/−; Rag2−/− mice (inflammation deficient) suggests that inducible microbial activities 
in addition to abundance are critical for E. coli–induced CRC.93 The inflammatory-derived 
factors influencing bacterial carcinogenic potential are unknown but could be secondary to 
inflammation-induced tissue damage (cell-derived nucleotides, amino acids, minerals, and 
so forth).
As opposed to E. coli and ETBF, F. nucleatum is not considered a proinflammatory 
bacterium in mice.96 Nevertheless, this microorganism has a profound impact on immune 
responses, an effect important for carcinogenesis. Flow cytometry on tumors from F. 
nucleatum–colonized mice and RNA-sequencing data of human CRC patients suggest a 
positive association between the bacteria and the presence of tumor-infiltrating myeloid 
cells.96 In vitro assays with primary human cells suggest that F. nucleatum is capable of 
interfering with host immunity by binding the human inhibitory receptor T cell 
immunoglobulin and ITIM domain (TIGIT) via its Fap2 surface protein, leading to 
inhibition of natural killer cell cytotoxicity and other T cell activities.97 A correlation has 
also been observed between F. nucleatum levels in human colorectal carcinoma tissue and 
reduced CD3+ T cells.98 Thus, F. nucleatum may promote immune evasion, one of the new 
hallmarks of cancer.72
Although Helicobacter hepaticus has not been associated with human CRC, infection of 
AOM/129SvEv.Rag2−/− with H. hepaticus is used to promote CAC in mice.99 IL-17+IL-22+ 
group 3 innate lymphoid cells (ILC3s) accumulate in the colon of H. hepaticus–infected 
AOM/129SvEv.Rag2−/− mice. Depletion of ILCs with anti-Thy1 or anti–IL-22 treatment 
reduced inflammation and tumors, suggesting a driving role for IL-22 producing ILC3s in H. 
hepaticus–induced CAC.99 Additional work suggests that ILC3-produced IL-22 promotes 
CAC by inducing epithelial cell proliferation and antimicrobial peptide production in a 
Stat3-dependent manner.99 Adaptive immune cells also produce IL-22, which cannot be 
studied in Rag2−/− mice, and therefore more investigations will be needed to address the role 
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of these cells. IL-22 may also play a role in human CRC, as there was higher IL-22 
expression in tumor tissue compared with normal tissue in 7 of 12 matched CRC patient 
samples; unfortunately, the role of bacteria in this observation is unknown.99 In summary, 
the microbiota affects and is affected by a range of host immune responses, all of which may 
contribute to CRC pathogenesis. Moreover, the impact of the intestinal microbiota on host 
immune responses extends beyond CRC, influencing both extraintestinal cancers and cancer 
therapeutics.
Microbiota, Drug Toxicity, and Cancer Therapy
The implication of the microbiota in cancer pathogen-esis has opened new opportunities for 
preventive or therapeutic intervention through microbiota manipulation, and various 
modalities (eg, antibiotics, probiotics, prebiotics, postbiotics, and so forth) have been 
proposed and tested in preclinical models.100-103 However, the modulatory impact of the 
microbiota on cancer extends beyond pathogenesis as recent evidence highlighted an 
interaction between bacteria and established cancer therapeutics. These bacteria–drug 
interactions originate from the extensive metabolic capacity and profound 
immunomodulatory effect of the microbiota (Fig 3).
Microbiota and drug toxicity. Chemotherapeutics
Chemotherapeutic drugs designed to target rapidly growing cancer cells are commonly used 
in cancer treatments but are frequently associated with severe cytotoxicity for the host.104 
For example, the prodrug irinotecan (CPT-11) is a topoisomerase I inhibitor typically used in 
patients with metastatic carcinoma of the colon.105 The prodrug is transformed into the 
active topoisomerase I inhibitor SN-38, which is further processed in the liver to form 
inactive SN-38G derivative. SN-38G is excreted via biliary ducts into the GI tract, where it 
is converted back to cyto-toxic SN-38 by bacterial β-glucuronidases. The presence of active 
SN-38 in the intestine causes severe diarrhea in a significant subset of patients, leading to 
dose reductions or treatment termination. Early studies showed that Kampo medicine 
(Hangeshashinto) and D-saccharic acid 1,4-lactone, both possessing inhibitory activities 
against β-glucuronidases, could alleviate CPT-11–induced diarrhea in patients and mucosal 
damage in rats, respectively.106,107 Subsequently, inhibitors of E. coli–derived β-
glucuronidase were shown to protect the host against CPT-11–induced GI toxicity in 
mice.108,109 These studies provide direct evidence that reactivation of SN-38G by the 
commensal gut micro-biota plays an essential role in CPT-11's toxic effect and suggests that 
targeting bacterial β-glucuronidases has great translational potential. More recently, 
representative β-glucuronidases were characterized from other commensal bacteria 
including the firmicutes Streptococcus agalactiae and Clostridium perfringens and the 
bacteroidetes B. fragilis.110 The β-glucuronidases produced by different bacteria display 
distinct catalytic properties and inhibition propensities.110 Future studies need to identify 
high potent inhibitors of these β-glucuronidases for clinical tests. Interestingly, while 
inducing CPT-11 toxicity in the intestine via β-glucuronidase activities, the microbiota could 
also promote resistance to the same drug by generating mucosal protective metabolites. 
Studies have shown that dietary fiber supplementation ameliorates CPT-11 toxicity without 
affecting microbial β-glucuronidase activity, a phenomenon attributed to high levels of 
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butyrate generated from microbial metabolism.111 This highlights the complexity of micro-
biota–drug interactions in the intestine.
Methotrexate (MTX) is another chemotherapeutic agent widely used in cancer 
treatments.112 Similar to CPT-11, MTX-induced GI toxicity is the major dose-limiting 
aspect for patient management.112 Although the precise pathophysiology underlying MTX-
associated GI toxic effects remains elusive, a recent study suggests that the gut microbiota is 
involved.113 Frank et al113 reported exacerbation of MTX-induced mucositis in mice lacking 
the innate receptor TLR2 compared with WT mice. Further investigation revealed that 
stimulation of TLR2 by the receptor agonist Pam3-CysSK4 protects against MTX-induced 
GI toxicity through activation of the multidrug efflux system ABCB1/(MDR)1 p-
glycoprotein.113 Importantly, microbiota depletion by antibiotics led to increased 
susceptibility to MTX-induced mucosal injury in WT mice.113 Together, the results suggest 
that microbial activation of TLR2 signaling attenuates MTX-induced GI toxicity. Whether 
microbial-driven TLR2 signaling plays a role in detoxifying other cancer drugs remains to 
be investigated.
Immune checkpoint blockade
Ipilimumab, an antibody against the immune checkpoint protein cytotoxic T-lymphocyte–
associated protein 4 (CTLA-4), is used mainly to treat metastatic melanoma and often leads 
to colitis development in patients because of poor function of Tregs.114 Recent studies 
showed that intestinal reconstitution of microbiota-depleted mice with the combination of B. 
fragilis and Burkholderia cepacia attenuated CTLA-4-blockade–induced histopathologic 
signs of colitis, likely via enhancing Treg response.115 Consistent with this observation, high 
abundance of gut bacteria belonging to the bacteroidetes phylum correlated with resistance 
to CTLA-4-blockade–induced colitis in patients.116 Thus, supplementation of B. fragilis and 
B. cepacia could be beneficial for patients undergoing ipilimumab treatment.
Microbiota and Cancer Therapy Efficacy
Chemotherapy
As mentioned previously, cancer drug efficacy could be influenced by the microbiota. A 
recent survey of in situ bacterial effects on frequently used chemotherapeutics suggests 
profound influence of distinct bacteria speciesonthe antitumor effect of these drugs.117 
Lehouritis et al found that after preincubation with nonpathogenic gram-negative E. coli 
Nissle 1917 or gram-positive Listeria welshimeri Serovar 6B SLCC5334, 10 of 30 
chemotherapeutic drugs (eg, gemcitabine, cladribine, daunorubicin, and so forth) showed 
reduced cancer cell killing efficacy, whereas 6 drugs (eg, fludarabine phosphate, CB1954, 
and so forth) showed increased cancer cell killing efficacy in vitro.117 High-performance 
liquid chromatography–mass spectrometry studies showed that these effects are often 
bacteria specific, likely because of the unique biotransforming activities associated with 
each bacterial species/strain.117 The in vitro bacteria-specific effect on drug cytotoxicity can 
be replicated in vivo using a xenograft mouse tumor (CT26 colon carcinoma) model.117 
Thus, bacteria could directly metabolize chemotherapeutic drugs to affect their efficacy. 
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Understanding the microbial pathways involved could help to improve cancer therapy 
outcomes.
Another means by which bacteria impact anticancer drug efficacy is through modulation of 
host inflammatory and immune responses. Viaud et al reported that nonmyeloablative doses 
of cyclophosphamide (CTX), a potent alkylating cytotoxic drug used to treat lymphomas 
and certain solid tumors,118 induced IL-17 and IFN-γ–expressing “pathogenic” Th17 
(pTh17) cells in the spleen, which mediate the therapeutic effect of the drug in xenograft 
(P815 mastocytoma and MCA205 sarcoma) and genetic (lung adenocarcinoma) mouse 
tumor models.119 Importantly, this antitumor immune response was diminished in GF, 
antibiotics-treated mice, or vancomycin (specific for gram-positive bacteria)-treated mice, 
indicating that gram-positive commensal bacteria are required for CTX efficacy. CTX 
treatment disrupted the small intestine barrier and facilitated translocation of commensal 
bacteria, particularly the gram-positive Lactobacillus johnsonii, Lactobacillus murinus, and 
Enterococcus hirae, into mesenteric lymph nodes and spleen. Oral administration of L. 
johnsonii and E. hirae, but not Lactobacillus plantarum, which did not translocate after CTX 
treatment, restored the pTh17 response in the spleen of antibiotics-treated mice.119 This 
study clearly demonstrates that specific gram-positive commensal bacteria contribute to the 
anticancer efficacy of CTX through engagement of host-derived immune response.
In support of this concept, a study led by Iida et al120 showed that the commensal microbiota 
promotes the antitumor effects of the platinum compounds oxaliplatin and cisplatin, as 
microbiota depletion by antibiotics reduced the efficacy of these drugs against subcutaneous 
tumors (EL4 lymphoma and MC38 colon carcinoma). Mechanistically, the commensal-
dependent reactive oxygen species production by myeloid cells is responsible, at least 
partially, for the efficacy of these platinum compounds. In line with the observation, Gui et 
al reported that antibiotic cotreatment reduced the efficacy of cisplatin in the Lewis lung 
cancer mouse model.
Immunotherapy
The work by Iida et al120 alsodemonstrated that the gut microbiota modulates theantitumor 
effect of CpG-oligonucleotide immunotherapy. The researchers found that combined anti–
IL-10R treatment and CpG-oligonucleotide immunotherapy slowed xenograft tumor growth 
(EL4 lymphoma, MC38 colon carcinoma, and B16 melanoma) and prolonged mouse 
survival by inducing tumor necrosis factor (TNF)-dependent cytotoxic CD8+ T cell response 
in the tumor environment, which is significantly impaired in microbiota-depleted or GF 
mice.120 Further investigation identified specific bacteria positively (eg, Alistipes, 
Ruminococcus) or negatively (eg, Lactobacillus) correlated with TNF production from 
tumor-associated myeloid cells.120 Oral administration of Alistipes shahii reconstituted TNF 
production by tumor-associated myeloid cells in microbiota-depleted mice, whereas gavage 
of Lactobacillus fermentum attenuated the response in SPF mice.120
More recently, specific commensals have been reported to mediate the antitumor effects of 
immune checkpoint blockers. Vetizou et al115 showed that anti–CTLA-4 antibody failed to 
inhibit tumor growth (MCA205 sarcoma, MC38 colon carcinoma, and Ret melanoma) in GF 
or antibiotics-treated mice because of defective antitumor Th1 response. Microbial profiling 
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identified bacterial species (eg, Bacteroides genus and species) associated with anti–
CTLA-4 treatment, and functional studies revealed that Bacteroides thetaiotaomicron, B. 
fragilis, and B. cepacia could stimulate the CTLA-4–induced antitumor immune response 
and thereby therapeutic efficacy.115 Clinically, the intestinal microbiota of patients with 
metastatic melanoma can be distinguished into 3 clusters: cluster A driven by the 
Alloprevotella or Prevotella, and clusters B and C by distinct Bacteroides spp.115 After 
ipilimumab (anti–CTLA-4) therapy, many cluster B patients switch to cluster C.115 Only 
mice colonized by cluster C, but not A or B fecal microbiota, showed increased abundance 
of B. fragilis, which negatively correlated with the antitumor effect of CTLA-4 blockade.115 
Thus, CTLA-4 blockade can modify the abundance of immunogenic Bacteroides spp., which 
in turn affect the efficacy of treatment.115
Programmed death–ligand 1 (PD-L1) is another immune checkpoint molecule targeted for 
cancer therapy and often used in combination with CTLA-4 blockade agents. Sivan et al122 
compared subcutaneous B16.SIY melanoma growth and response with PD-L1 blockade in 
C57BL/6 mice obtained from Jackson Laboratory (JAX) and Taconic Farms (TAC). These 
mice have previously been shown to display different intestinal microbiota and immune 
responses.123 Interestingly, tumors grew more aggressively in TAC mice, which are 
paralleled by dampened tumor-specific T cell responses compared with JAX mice.122 
Moreover, the TAC phenotype can be reversed by cohousing or transplanting JAX fecal 
materials, suggesting that the mi-crobiota drives the differential phenotype.122 PD-L1 
blockade showed better outcomes in JAX mice than TAC, as assessed by tumor growth 
inhibition and anti-tumor CD8+ T cell response.122 Microbiota analyses revealed that 
Bifidobacterium was strongly associated with the antitumor T cell response.122 Strikingly, 
oral gavage of a Bifidobacterium species cocktail, which included Bifidobacterium breve 
and Bifidobacterium longum, significantly decreased tumor growth in TAC mice and when 
combined with PD-L1 blockade abolished tumor growth.122 Mechanistically, the researchers 
showed that dendritic cells play a role in bridging Bifidobacterium-derived signals and the 
antitumor immune response.122 These findings support the concept that bacteria strongly 
influence the antitumor efficacy of drugs targeting immune checkpoint molecules. Because 
these studies were mostly conducted with xenograft models, the clinical relevance of the 
findings will need to be extended in model with primary tumors. Nevertheless, it is clear that 
the microbiota has tremendous impact on cancer therapeutics (efficacy–toxicity) and this 
“drug–bug” interaction deserves further mechanistic investigation and translational 
validation.
Conclusion and Future Directions
The microbiome is deeply embedded in human metabolic function and represents an integral 
part of host homeostasis. The impact of this microbiota on homeostasis starts early at birth 
and is sustained throughout life, with modifying pressure coming from environmental cues 
such as lifestyle and diet. Therefore, it is not surprising that disruption of the microbial 
ecosystem has repercussions on host homeostasis, which could lead to pathologies such as 
cancer (Fig 4). The wide impact of the microbiota on the carcinogenic process is remarkable 
and spans initiation, progression, tumor evasion, and therapeutic responses. The long-
distance impact of the intestinal microbiota on carcinogenesis suggests that cancer in a given 
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organ is not strictly linked to a local biota, again showing the wide networking activities of 
microorganisms.
Despite all the connections made between the microbiota and carcinogenesis, numerous 
questions remain unanswered. For example, it is unclear how microbial dysbiosis influences 
tumorigenesis (local or long distance) and whether ensembles of microbial activities 
(protective and deleterious) are at play in the process. Are these activities originating from 
tissue-associated or planktonic microorganisms? The biotransformation capacity of the 
intestinal microbiota is certainly an important element in the selection and maintenance of 
microbial consortia throughout evolution. Linking functional anticarcinogenic nutrients to 
biotransformative ability of specific microorganisms would have a tremendous impact in 
cancer prevention. An exciting and emerging field of research in microbiome cancer is 
undeniably the interaction between bacteria and anticancer drugs. However, it is imperative 
to strengthen this field of research and document the interaction between anti-cancer 
therapies and bacteria using preclinical primary tumor models to ascertain the physiological 
impact of bacteria in cancer therapeutics. Although challenging to set up, studies linking 
treatment outcomes using specific drugs with that of intestinal microbial composition would 
help define the physiological impact of drug–bug interactions. In addition, identification of 
microbes and microbial genes responsible for drug biotransformation as well as the specific 
immune cells engaged by microbes and implicated in the therapeutic response should be 
investigated. As more mechanistic understandings emerge from this new drug–bug field of 
research, one could envision pairing bacteria (or bacterial-derived molecules) with a given 
compound to obtain maximum efficacy and lower toxicity.
In summary, microbiota unifies numerous processes including nutrition, metabolism, and 
immunity, which represent key biological activities for carcinogenesis, and it is clear that the 
microbiota-cancer is not a flash in the pan but rather a transformative new field of research 
that would likely impact the way cancer is detected, treated, and managed in the future.
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AOM azoxymethane
Apc adenomatous polyposis coli
CAC colitis associated cancer
CRC colorectal cancer
DNA-PK DNA-dependent protein kinase
GF germ free
GI gastrointestinal
IBD inflammatory bowel diseases
IL interleukin
MAIT mu-cosa-associated invariantT
MTX methotrexate
NLR NOD-like receptor
NLRP1 NLR family, pyrin domain containing 1
NOD nucleotide-binding oligomerization domain-containing protein
PDL-1 programmed cell death protein1ligand1
Pope et al. Page 20
Transl Res. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
PI3K phosphoinositide 3-kinase
PRR pattern recognition receptors
SCFA short chain fatty acids
TIGIT T cell immunoglobulin and ITIM domain
TLR toll-like receptors
Tregs regulatory T cells
WT wild type
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Fig 1. 
The microbiota regulates the balance between health and disease. A combination of external 
factors can influence microbial composition, including host genetics, diet, lifestyle, and 
environmental factors. These perturbations in the microbiota shift the balance between 
healthy and carcinogenesis.
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Fig 2. 
Interplay among the microbiota, host immunity, and CRC. The intestinal microbiota induces 
a variety of host immune responses (brown arrows) including cytokine production, PRRs, 
inflammasomes, and autophagy, all of which contribute to cancer development. The 
microbiota induces the proinflammatory cytokines IL-23, IL-17A, and IL-17C, which 
promote CRC. The PRRs Nod2 and Aim2 and the Nlrp6 inflammasome protect against 
tumor-igenesis by regulating epithelial proliferation and may contribute to eubiosis. Nlrp3 
suppresses metastatic growth to the liver, a phenotype which is unaffected by antibiotics. 
The autophagy gene Atg7 promotes tumorigenesis in an Apc model by promoting 
proliferation and decreasing the antitumor CD8+ T cell response. CRC, colorectal cancer; 
IL, interleukin; PRR, pattern recognition receptor. (For interpretation of the references to 
color in this figure legend, the reader is referred to the Web version of this article.)
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Fig 3. 
Interaction between bacteria and anticancer drugs. The microbiota influences anticancer 
drug efficacy and toxicity through direct or indirect mechanisms. Bacterial β-glucuronidases 
convert SN-38G to active SN-38, leading to the toxic effect of CPT-11. Microbiota can 
generate barrier-protective metabolites such as butyrate and activate TLR2/drug efflux 
response to attenuate CPT-11 and MTX toxicity, respectively. B. fragilis (via Treg response) 
and B. cepacia can ameliorate CTLA-4-blockade–induced intestinal inflammation. On the 
other hand, bacteria profoundly influence the efficacy of chemotherapeutics via a metabolic 
route. Microbial-driven ROS production by tumor-associated inflammatory cells promotes 
the antitumor effect of oxaliplatin and cisplatin. A. shahii induces TNF production by tumor-
associated myeloid cells, which contributes to the antitumor effect of CpG-ODN. Efficacies 
of CTX, CTLA-4 blockade, and PD-L1 blockade can be enhanced by specific and distinct 
bacteria. CpG-ODN, CpG-oligonucleotide; CPT, irinotecan; CTLA, cytotoxic T-
lymphocyte–associated protein 4; MTX, methotrexate; ROS, reactive oxygen species; TLR, 
toll-like receptor; TNF, tumor necrosis factor.
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Fig 4. 
Gut microbiota regulates carcinogenesis at various levels. Perturbations in the healthy 
microbiota lead to dysbiosis, increasing the number of procarcinogenic bacteria that can 
have local or long-distance effects. Healthy microbiota can biotransform anticancer 
therapeutic drugs, impacting their toxicity and efficacy. In addition, cancer therapeutics can 
function synergistically with the immune system to inhibit cancer.
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